前列腺癌挽救治疗:AUA/ASTRO/SUO指南第三部分:放疗或局灶治疗后的挽救治疗、盆腔淋巴结复发与寡转移及未来方向
该指南由AUA、ASTRO与SUO联合制定,基于截至2022年7月21日的系统检索及2023年7月26日的更新检索,针对放疗或局灶治疗后疑似非转移性复发、区域复发及分子影像转移性复发的评估与管理提出循证与共识推荐,旨在辅助临床决策。
要点
- 指南涵盖放疗或局灶治疗后疑似非转移性复发的评估与管理推荐。
- 指南涵盖区域复发及分子影像转移性复发的管理推荐。
- 指南强调未来需持续开展多学科协作以优化挽救治疗的肿瘤学与功能结局。
核心结论
- 未来需持续且有针对性地开展前列腺癌多学科协作,以优化和改善接受挽救治疗患者的肿瘤学与功能结局。
研究设计与样本
- 由AUA、ASTRO与SUO联合制定的循证与共识指南,基于Ovid MEDLINE(1946年至2022年7月21日)、Cochrane对照试验中心注册库(至2022年8月)及Cochrane系统评价数据库(至2022年8月)的系统检索,并于2023年7月26日进行更新检索。
关键数值与推荐
- 指南就放疗或局灶治疗后疑似非转移性复发的评估与管理提出推荐。
- 指南就区域复发的评估与管理提出推荐。
- 指南就分子影像转移性复发的管理提出推荐。
临床怎么用
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part III of a three-part series focusing on evaluation and management of suspected non-metastatic recurrence after radiotherapy (RT) and focal therapy, evaluation and management of regional recurrence, management for molecular imaging metastatic recurrence, and future directions. Please refer to Part I for discussion of treatment decision-making and Part II for discussion of treatment delivery for non-metastatic biochemical recurrence (BCR) after radical prostatectomy (RP). MATERIALS AND METHODS: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE (1946 to July 21, 2022), Cochrane Central Register of Controlled Trials (through August 2022), and Cochrane Database of Systematic Reviews (through August 2022). Update searches were conducted on July 26, 2023. Searches were supplemented by reviewing electronic database reference lists of relevant articles. RESULTS: In a collaborative effort between AUA, ASTRO, and SUO, the Salvage Therapy for Prostate Cancer Guideline Panel developed evidence- and consensus-based guideline statements to provide guidance for the care of patients who experience BCR after initial definitive local therapy for clinically localized disease. CONCLUSIONS: Continuous and deliberate efforts for multidisciplinary care in prostate cancer will be required to optimize and improve the oncologic and functional outcomes of patients treated with salvage therapies in the future.
引用
- Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024. PMID: 38421252. doi:10.1097/JU.0000000000003890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。